Core Insights - Damora Therapeutics has appointed Jennifer Jarrett as President and CEO, effective March 30, 2026, bringing nearly three decades of experience in biotech, tech, and finance [1][2] - The company aims to redefine care for patients with blood disorders, particularly focusing on mutant calreticulin-driven myeloproliferative neoplasms (MPNs) [2][7] - The Board of Directors has also appointed Cameron Turtle and Mike Landsittel, enhancing the board's expertise in biotech and capital markets [3][4] Company Leadership - Jennifer Jarrett has a strong background in corporate strategy, finance, and drug development, previously serving as COO of Arcus Biosciences and CFO of Medivation [2][5] - Peter Harwin has been named Chairman of the Board, emphasizing the strategic direction of the company [3][4] - Cameron Turtle and Mike Landsittel bring extensive experience in building and leading biotech companies, with Turtle focusing on development and commercialization and Landsittel on strategic finance [5][6] Strategic Focus - Damora is advancing a portfolio of potential best-in-class therapies aimed at treating MPNs, with plans to enter clinical development in 2026 [7] - The company is positioned to rapidly develop its lead program, DMR-001, while also advancing additional pipeline assets [2][7] - The board acknowledges the contributions of departing directors, highlighting the strategic importance of recent transactions [5]